DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Gantz I, Chen M, Suryawanshi S. et al.
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
Cardiovasc Diabetol 2017;
16 (01) 112
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.